ACRO Biomedical Reports No Revenue and Increased Losses in Q3 2025

ACRO Biomedical Co., Ltd. reported its financial results for the third quarter of 2025, revealing a continued lack of revenue generation. The company reported no revenue for both the three and nine months ended September 30, 2025, mirroring the same period in the previous year. Operating expenses for the third quarter increased significantly to $115,099, compared to $9,106 in the same quarter of 2024. For the nine-month period, operating expenses rose to $137,647 from $28,490 year-over-year. The net loss for the third quarter was $117,809, compared to a loss of $10,229 in the prior year, while the nine-month net loss escalated to $143,672 from $31,624.

The company's financial position has deteriorated, with total current assets dropping to $4,323 as of September 30, 2025, down from $5,076 at the end of 2024. Current liabilities increased by 33.6% to $436,942, resulting in a working capital deficiency of $432,619, a 34.4% increase from the previous period. The company’s accumulated deficit also widened to $32,801,467 from $32,657,795. The lack of revenue and increasing losses raise substantial doubt about the company's ability to continue as a going concern.

Operationally, ACRO Biomedical has not made any sales since December 31, 2022, and has not developed any new products from its research and development activities. The company has relied heavily on advances from a minority stockholder to fund operations, with $174,772 provided in financing activities during the nine months ended September 30, 2025. The company currently has no full-time employees, with its chief executive officer working part-time without compensation. This limited workforce and reliance on external funding sources pose significant risks to the company's future operations.

In terms of strategic developments, ACRO Biomedical has not reported any new product launches or acquisitions. The company has faced challenges due to the COVID-19 pandemic and its impact on the Chinese market, which has historically been a significant customer base. The company’s stock is currently traded on the OTC Market Group’s Pink Limited Market, which limits its marketability and raises concerns about liquidity and investor interest.

Looking ahead, ACRO Biomedical's management has indicated that the company plans to seek funding through product sales and equity financing arrangements. However, with no current orders for products and a lack of market presence, the outlook remains uncertain. The company acknowledges the risks associated with its financial condition and the potential inability to generate revenue, which could hinder its ability to continue operations.